Skip to main content
. 2021 Jan 18;35(5):1057–1066. doi: 10.1007/s10557-020-07134-2

Fig. 5.

Fig. 5

Summary of subgroup analyses for proportions of responders with normokalemia between the SZC and placebo group. >50% CKD: the proportion of patients with CKD was larger than 50% in the included studies; SZC, Sodium zirconium cyclosilicate; CKD, chronic kidney disease; DM, diabetic mellitus; RAASi, renin-angiotensin aldosterone system inhibitor; tid: three times daily; qd: once daily; HF, heart failure